CALGARY, Feb. 11, 2014 /CNW/ - Zenith Epigenetics announced today that Arthur Higgins will be stepping down from the Board of Directors after fulfilling his commitment in helping Zenith Epigenetics to be established as a spin out company from Resverlogix Corp. Zenith Epigenetics' management and Board of Directors would like to thank Arthur for his commitment and positive input during this time.
In addition, Zenith Epigenetics Corp. will be hosting a conference call and webcast on Thursday, February 20, 2014 at 11 am MDT / 1 pm ET. The call will update the market on current developments and clinical progress.
Details for the conference call and webcast are as follows:
Link to webcast: http://services.choruscall.ca/links/zenith140220.html
Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340
Zenith Epigenetics Corp. is a research and development biotechnology company focused on new and innovative drugs by leveraging its proprietary epigenetics platform. The company's epigenetic drug discovery platform functions by inhibiting BET bromodomains, having the potential to impact multiple diseases including autoimmune and oncology.
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Donald J. McCaffrey
President and CEO
Zenith Epigenetics Corp.
Email: [email protected]
SOURCE: Zenith Epigenetics Corp.